119 related articles for article (PubMed ID: 1329287)
1. Ganciclovir treatment for cytomegalovirus infections in renal transplant recipients.
Buturović-Ponikvar J; Kandus A; Malovrh M; Ponikvar R; Kveder R
Transplant Proc; 1992 Oct; 24(5):1921-3. PubMed ID: 1329287
[No Abstract] [Full Text] [Related]
2. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation.
van Son WJ; van den Berg AP; The TH; Tegzess AM
Transplant Proc; 1993 Feb; 25(1 Pt 2):1436-8. PubMed ID: 8382873
[No Abstract] [Full Text] [Related]
3. Optimization of cyclosporine monotherapy--long-term graft function.
Birkeland SA; Elbirk A; Rohr N; Jørgensen KA
Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
[No Abstract] [Full Text] [Related]
4. Late acute rejection in renal transplant recipients: response to steroid treatment.
Prieto C; Pulido F; Rodríguez-Paternina E; Algranati C; Bello I; Farias J; G-Millet V
Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
[No Abstract] [Full Text] [Related]
5. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
[No Abstract] [Full Text] [Related]
6. Treatment of cytomegalovirus infections with gancyclovir during OKT3 administration.
Haberal M; Velidedoğlu E; Arslan G; Bilgin N; Büyükpamukçu N; Karamehmetoğlu M
Transplant Proc; 1995 Oct; 27(5):2707. PubMed ID: 7482883
[No Abstract] [Full Text] [Related]
7. Triple drug maintenance therapy in renal transplantation.
Pallardó LM; Sánchez J; Hernandez M; Górriz JL; Sánchez P; Beneyto I; Rochera A
Transplant Proc; 1992 Feb; 24(1):58-9. PubMed ID: 1539343
[No Abstract] [Full Text] [Related]
8. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
9. Comparative efficacy of prophylactic monoclonal (OKT3) and polyclonal antibodies (ATG) in immunologic high-risk renal transplant recipients.
Fukuuchi F; Lefrançois N; Chapuis F; Gebuhrer L; Bosshard S; Dubernard JM; Touraine JL
Transplant Proc; 1996 Oct; 28(5):2808-9. PubMed ID: 8908070
[No Abstract] [Full Text] [Related]
10. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
Troppmann C; Almond PS; Payne WD; Dunn DL; Gores PF; Gruessner RW; Sutherland DE; Matas AJ; Najarian JS
Transplant Proc; 1993 Feb; 25(1 Pt 2):905. PubMed ID: 8442263
[No Abstract] [Full Text] [Related]
11. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients.
Klauser R; Zlabinger GJ; Traindl O; Franz M; Watschinger B; Pohanka E; Kudlacek S; Kovarik J
Transplant Proc; 1992 Feb; 24(1):292-4. PubMed ID: 1539284
[No Abstract] [Full Text] [Related]
12. Cytokine-release syndrome: differences between high and low doses of OKT3.
Norman DJ; Kimball JA; Barry JM
Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
[No Abstract] [Full Text] [Related]
13. Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction.
Ham JM; Shelden SL; Godkin RR; Posner MP; Fisher RA
Transplant Proc; 1995 Oct; 27(5 Suppl 1):31-3. PubMed ID: 7482814
[No Abstract] [Full Text] [Related]
14. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH
Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
[No Abstract] [Full Text] [Related]
15. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
[TBL] [Abstract][Full Text] [Related]
16. Renal allograft rejection in a patient with the Wiskott-Aldrich syndrome.
Meisels IS; Strom TB; Roy-Chaudhury P; Abrams J; Shapiro ME
Transplantation; 1995 Apr; 59(8):1214-5. PubMed ID: 7732568
[No Abstract] [Full Text] [Related]
17. Treatment of steroid resistant acute rejection after renal transplantation.
Oh CK; Kim YS; Kim MS; Kim SI; Park K
Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
[No Abstract] [Full Text] [Related]
18. Cytomegalovirus infection during OKT3 treatment for renal allograft rejection.
Morgan JD; Horsburgh T; Simpson A; Donnelly PK; Veitch PS; Bell PR
Transplant Proc; 1992 Dec; 24(6):2634-5. PubMed ID: 1334589
[No Abstract] [Full Text] [Related]
19. Relative clinical impact of cyclosporine vs steroid induction therapy on renal function and allograft rejection in heart transplant recipients.
Hanrahan JS; Ibrahim H; Tolman D; Kirchberg D; Salter D; Guerraty A; Mohanty PK
Transplant Proc; 1996 Aug; 28(4):2107-8. PubMed ID: 8769168
[No Abstract] [Full Text] [Related]
20. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G
Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
[No Abstract] [Full Text] [Related]
[Next] [New Search]